NJ Bio, Inc. has been recognized by its long-standing client, Exelixis, for delivering outstanding service in 2025. This recognition highlights the company’s strong scientific and technical expertise, the innovative implementation of innovative solutions, and expansion into bioconjugation. Exelixis also acknowledged NJ Bio’s exceptional manufacturing performance, including GMP lots that exceeded expectations, and strong project execution through seamless cross-functional collaboration. NJ Bio sincerely thanks the Exelixis team for being incredible partners and for their continued support, guidance, and close collaboration throughout this journey.
We also congratulate the entire NJ Bio team for their hard work and unwavering commitment to excellence. These collective efforts continue to deliver meaningful impact and strengthen the value brought to clients. We believe that NJ Bio’s technical expertise, innovative solutions, robust clinical batch delivery record, and expanding bioconjugation capabilities will continue to support Exelixis’s mission to help cancer patients recover stronger and live longer.